|
| Press Releases |
|
 |
|
| Wednesday, April 15, 2015 |
|
|
Nanobiotix: 2014 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its audited consolidated results for the fiscal year ended December 31, 2014. more info >> |
|
| Tuesday, February 24, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Monday, February 23, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Friday, February 20, 2015 |
|
|
Professor Robert Langer joins Nanobiotix as Scientific Advisor |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced that Professor Robert Langer, Institute Professor at the Massachusetts Institute of Technology (MIT), has become Scientific Advisor to Nanobiotix. more info >> |
|
| Thursday, October 16, 2014 |
|
|
Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) announced today that it has received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, October 8, 2014 |
|
|
PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205- PEA PME eligible), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer today announces the update of the development plan for NBTXR3. more info >> |
|
| Monday, June 2, 2014 |
|
|
Nanobiotix Presents Successful Phase I Results for Its Lead Nanomedicine Product NBTXR3 at ASCO |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented today at the American Society of Clinical Oncology annual meeting. more info >> |
|
| Tuesday, February 11, 2014 |
|
|
NANOBIOTIX sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its development plan for the CE marking of NBTXR3, the first product from the NanoXray pipeline. more info >> |
|
| Friday, December 6, 2013 |
|
|
NANOBIOTIX Strengthens its NanoXray Pipeline with the Launch of NBTX-TOPO Development, the First Nanotherapeutic with Embedded Radar |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today, in accordance with its plans, the selection of its new product, NBTX-TOPO, in view of its preclinical development. more info >> |
|
| Monday, September 23, 2013 |
|
|
NANOBIOTIX Strengthens Its Management Team |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the strengthening of its management team to support the company's growth within its business strategy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Leapfrog Acquisition Corp Announces Pricing of $125,000,000 Initial Public Offering
Dec 5, 2025 18:50: JST
|
|
|
Leapfrog Acquisition Corp Announces Pricing of $125,000,000 Initial Public Offering
Dec 5, 2025 17:50 HKT/SGT
|
|
|
Business of IP Asia (BIP Asia) Forum and Entrepreneur Day open today
Dec 5, 2025 15:41 HKT/SGT
|
|
|
心系大埔火災災情 斯派柯急援300萬港元助重建
Dec 5, 2025 15:13 HKT/SGT
|
|
|
三菱造船と日本製鉄が低圧液化CO₂タンクの新規鋼材と熱処理（PWHT）省略技術を開発
Dec 5, 2025 11:30: JST
|
|
|
LEXUS、バッテリーEVスポーツカーのコンセプトモデル「Lexus LFA Concept」を世界初公開
Dec 5, 2025 11:20: JST
|
|
|
Business of IP Asia (BIP Asia) Forum and Entrepreneur Day open today
Dec 4, 2025 22:00: JST
|
|
|
Doubleview Extends High-Grade Domains at Hat: H099 Returns 438m of 0.40% CuEq Including 52m of 1.02% CuEq, Expanding Mineralization Envelope Around Conceptual Pit Vertically and Laterally
Dec 4, 2025 21:59 HKT/SGT
|
|
|
CaoCao Unveils '100 Cities, 100 Billion in 10 Years' Robotaxi Strategy, Officially Launches World's First 'Green Intelligent Mobility Hub'
Dec 4, 2025 21:00 HKT/SGT
|
|
|
曹操出行發佈Robotaxi「十年百城千億」戰略目標 全球首個「綠色智慧通行島」正式啟用
Dec 4, 2025 18:18 HKT/SGT
|
|
|
The Gourmet's Guide: Using Your TravelKon eSIM to Hunt for Japan's Best Ramen, Sushi, and Street Food
Dec 4, 2025 17:45 HKT/SGT
|
|
|
Spritzer Celebrates Global and Regional Brand Excellence 2025
Dec 4, 2025 12:45 HKT/SGT
|
|
|
Honda、新型「CR-V」の先行予約開始
Dec 4, 2025 11:30: JST
|
|
|
在聯泓格潤「超級工廠」看見綠色材料全鏈路
Dec 4, 2025 09:36 HKT/SGT
|
|
|
在联泓格润"超级工厂" 看见绿色材料全链路
Dec 4, 2025 09:14 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
